tiprankstipranks
The Fly

Legend Biotech price target lowered to $80 from $82 at Morgan Stanley

Legend Biotech price target lowered to $80 from $82 at Morgan Stanley

Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating on the shares. The firm updated its model to reflect quarter-over-quarter trends anticipated for Carvykti in 2025 and to moderate its 2025-plus ex-U.S. Carvykti ramp expectations.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com